3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Interventions
Doxorubicin
8
Ifosfamide
6
Radiotherapy
4
Dacarbazine
3
Trabectedin
2
Filgrastim
2
pegfilgrastim
1
olaratumab
1
indolepropanol phosphate
1
anlotinib
1
Watchful Waiting
1
Tablets
1
Surgical Procedures, Operative
1
Rosuvastatin Calcium
1
Radiotherapy, Conformal
1
PM 01183
1
Observation
1
Neoadjuvant Therapy
1
Midazolam
1
Etoposide
1
Digoxin
1
Diathermy
1
Combined Modality Therapy
1
Chemotherapy, Adjuvant
1
ADI PEG20
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Leiomyosarcoma
×
olaratumab
×
Clear all
NCT02451943
2025-07-15
ANNOUNCE
Eli Lilly and Company
Phase 3
Completed
509 enrolled
23 charts